OABI
NASDAQ
Life Sciences Tools & Services
$2.08
USD
-$0.04 (-1.89%)
At close: Jul 20, 2026, 4:00 PM EDT
Market Cap:
$307.34M
Volume:
292.4K
Previous Close
$2.12
Day Range
$2.05 - $2.15
52 Week Range
$1.30 - $2.79
Average Volume (10 Days)
590.0K
P/E Ratio (TTM)
—
Dividend Yield
—
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 89 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
CEO
Mr. Matthew Foehr
Headquaters
Emeryville, CALIFORNIA, US
Founded
2020
Employees
89
TKNO
Alpha Teknova Inc
$5.30
-2.2%
MLAB
Mesa Laboratories Inc
$96.67
-1.3%
CDXS
Codexis Inc
$2.21
-1.3%
PACB
Pacific Biosciences of California Inc
$1.36
-5.6%
LFCR
Lifecore Biomedical Inc
$4.69
+0.2%